Tuesday, November 20, 2007

Erbitux Improves Survival In Metastatic Colorectal Cancer - Study

Medical News Today - Merck Serono has leading brands serving patients with cancer (Erbitux®), multiple sclerosis (Rebif®), infertility (Gonal-f®), metabolic and cardiometabolic disorders (Glucophage®, Concor®, Saizen®, Serostim®), as well as psoriasis (Raptiva Read More

0 comments: